Recent News
Former Board Chairman Dr. Tom Lynch, New President and Director at Fred Hutchinson Cancer Research Center, to Remain a […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates against a range of hematological and solid tumors
Our Technologies
News
KP1237, a CD38-Targeting Antibody Recruiting Molecule (ARM™), to Be Tested in Combination with NK Cells to Treat Post-Transplant Multiple Myeloma […] Read More
We have noticed the emergence of an interesting trend that is popping up in the emerging biopharmaceutical industry: platform technologies, […] Read More
New Haven, CT, December 18, 2019/PRNewswire/– Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to […] Read More
Events
AACR – American Association for Cancer Research
ASCO – American Society of Clinical Oncology
BIO International Convention
